Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 18/20 | 0.66 |
| ▸ | AGXT | P21549 | 4/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9342733 | 0.83 | PYCR1 (0.45) | IDO1PYCR1MAPK1SMN1; SMN2 | |
| SCHEMBL25394603 | 0.80 | IDO1 (0.66) | IDO1AGXT | |
| SCHEMBL9767549 | 0.79 | IDO1 (1.00) | IDO1AGXTMAPK1SMN1; SMN2 | |
| SCHEMBL9343490 | 0.78 | PYCR1 (0.41) | IDO1PYCR1MAPK1SMN1; SMN2 | |
| SCHEMBL12229609 | 0.78 | IDO1 (0.68) | IDO1AGXTMAPK1 | |
| Hydrochloric Acid SCHEMBL1715908 | 0.78 | IDO1 (1.00) | IDO1AGXTMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1715890 | 0.78 | IDO1 (1.00) | IDO1AGXTMAPK1SMN1; SMN2 | |
| SCHEMBL2551704 | 0.77 | PNMT (0.48) | IDO1PYCR1MAPK1 | |
| SCHEMBL1520757 | 0.76 | IDO1 (0.66) | IDO1AGXT | |
| SCHEMBL18348140 | 0.76 | PYCR1 (0.40) | IDO1PYCR1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-115776891-A | STAT degradants and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-2726482-B1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | IDO1 41/4885AGXT 112/4885PYCR1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.